Health TrialsbyHealthPanel

Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4

ConditionCancer
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorInstitut Curie

About this trial

Multi-cohort exploratory prospective study. Participation in the ALCINA 4 study does not change the standard management of the patient, including the treatments administered. A sampling schedule will be set up for each cohort.

Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples (or more) taken per patient for up to 18, 24 or 36 months. If a specific tumor sample is required, it will be collected only once during the study.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient treated for cancer at one of the participating center

18 years old or higher

Signed informed consent form

Patient not deprived of their liberty or under guardianship (including temporary guardianship)

Disqualifiers

None

Trial design

Design model

Parallel

Treatments tested in this trial

  • Blood sample

    Other intervention

    Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples (or more) taken per patient for up to 18, 24 or 36 months according to the cohorts.

  • Biopsy

    Other intervention

    If a specific tumor sample is required, it will be collected only once during the study

Treatment groups

2,050 Participants
are divided into 12 treatment groups

12

Treatment groups

See each treatment group below.

Group A: Cohort 1: "SENOLOC"Other 1 intervention
Group B: Cohort 2: "Immuno-TNBC "Other 2 interventions
Group C: Cohort 3: "Trans-TNBC"Other 1 intervention
Group D: Cohort 4: "Treg"Other 2 interventions
Group E: Cohort 5: "Pembro Neo"Other 2 interventions
Group F: Cohort 6: "THL"Other 2 interventions
Group G: Cohort 7:"CDK4/6 adjuvant"Other 1 intervention
Group H: Cohort 8:"ctDNA adjuvant "Other 2 interventions
Group I: Cohort 9:"ADN-CIRC-Poumon "Other 2 interventions
Group J: Cohort 10: "UM TENEO"Other 2 interventions
Group K: Cohort 11: L1 CDK4/6Other 1 intervention
Group L: Cohort 12: PDXOther 2 interventions

Trial outcomes

Primary outcomes

1

Detection rate of circulating biomarkers in cohort 1

Positivity rate of the detection technique (in %)

Time frame
Baseline
2

Detection rate of circulating biomarkers in cohort 2

Positivity rate of the detection technique (in %)

Time frame
Baseline
3

Detection rate of circulating biomarkers in cohort 2

Positivity rate of the detection technique (in %)

Time frame
Before treatment
4

Detection rate of circulating biomarkers in cohort 2

Positivity rate of the detection technique (in %)

Time frame
At 3 weeks of treatment

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Institut Curie

Lead sponsor

Source ClinicalTrials.gov
Apply now